ArticleClinical drug investigation2020

Pembrolizumab vs the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.

Yitian Lang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.